{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:25:07Z","timestamp":1792182307439,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004028.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000}}],"reference-count":195,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004028.pub4","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T22:31:43Z","timestamp":1480026703000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Valproate for schizophrenia"],"prefix":"10.1002","volume":"2016","author":[{"given":"Yijun","family":"Wang","sequence":"first","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen; Neuro-Cognitive Psychology Master Program; Thalkirchner Str. 9 Munich Bavaria Germany D-80337"},{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaningerstrasse 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health University of Nottingham Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Helfer","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaningerstrasse 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbo","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Psychotic Disorders; 600 Wan Ping Nan Road Shanghai China 200030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaningerstrasse 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"10.1002\/14651858.CD004028.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.npp.1300023","article-title":"Effect of divalproex combined with olanzapine or risperidone in participants with acute exacerbation of schizophrenia","volume":"28","author":"Casey","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ps.55.3.290","article-title":"Adjunctive divalproex and hostility among participants with schizophrenia receiving olanzapine or risperidone","volume":"55","author":"Citrome","year":"2004","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0003|cit3","unstructured":"Jafari M Jiang P Casey DE Adjunctive divalproex sodium lowers cholesterol elevation with olanzapine 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA 2004"},{"issue":"5","key":"10.1002\/14651858.CD004028.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/npp.2008.209","article-title":"Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia","volume":"34","author":"Casey","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0005|cit5","unstructured":"M02-547 A randomized, double-blind study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs. an atypical antipsychotic alone in the treatment of schizophrenia www.abbvie.com\/content\/dam\/abbviecorp\/us\/desktop\/research\/clinical-trials-data-and-information-sharing\/synopses\/divalproex%20sodium_M02-547.pdf"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0006|cit6","unstructured":"NCT00073164 A study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs an atypical antipsychotic alone in the treatment of schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00073164"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0009|cit7","unstructured":"Citrome L Schizophrenia and valproate Psychopharmacology Bulletin 2003 74 88"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0007|cit8","unstructured":"Citrome L Daniel D Wassef A Tracy K Wozniak P Casey D Antipsychotic monotherapy versus combination treatment with valproate in hospitalized patients with acute schizophrenia: a double-blind, multi-center study Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002 NR316"},{"issue":"6","key":"10.1002\/14651858.CD004028.pub4-BIB0008|cit9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/YIC.0b013e3281c61baf","article-title":"Risperidone alone versus risperidone plus valproate in the treatment of participants with schizophrenia and hostility","volume":"22","author":"Citrome","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0010|cit10","unstructured":"NCT00308360 Risperidone alone vs risperidone plus valproate in the treatment of participants with schizophrenia and hostility clinicaltrials.gov\/ct2\/show\/NCT00308360"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Nolan K Shope C Citrome L Volavka J Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study Psychiatric Quarterly 2009 167 72","DOI":"10.1007\/s11126-009-9104-8"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0013|cit12","volume-title":"Die Bedeutung von Antikonvulsiva und Calciumantagonisten f\u00fcr die Pharmakotherapie von Psychosen. Habilitationsschrift","author":"Dose","year":"1991"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0012|cit13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-2007-979312","article-title":"Combined treatment of schizophrenic psychoses with haloperidol and valproate","volume":"31","author":"Dose","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1192\/bjp.150.4.542","article-title":"The effect of sodium valproate on tardive dyskinesia - revisited","volume":"150","author":"Fisk","year":"1987","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/JCP.0b013e3181a443d0","article-title":"A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for participants with schizophrenia who are stabilized and partially responsive","volume":"29","author":"Glick","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0016|cit16","first-page":"183","article-title":"Study of quetiapine combined with magnesium valproate release tablets in treatment of schizophrenia with symptoms of elation and agitation","volume":"17","author":"Guo","year":"2007","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00004714-199908000-00005","article-title":"Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic participants","volume":"19","author":"Hesslinger","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0018|cit18","unstructured":"Normann C Klose P Hesslinger B Langosch J Berger M Walden J Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co-medication: a clinical trial PharmacoPsychiatry 1997 204"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0019|cit19","unstructured":"Walden J Hesslinger B Normann C Langosch J Berger M Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998"},{"issue":"5","key":"10.1002\/14651858.CD004028.pub4-BIB0020|cit20","first-page":"310","article-title":"Effect of sodium valproate on serum concentration and clinical efficacy of clozapine","volume":"17","author":"Jia","year":"2007","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0021|cit21","first-page":"175","article-title":"The effect of adjuvant magnesium valproate sustained - release tablets for schizophrenia with agitation and agitation.","volume":"15","author":"Jiang","year":"2009","journal-title":"Chinese Magazine of Drug Abuse Prevention and Treatment [\u4e2d\u56fd\u836f\u7269\u6ee5\u7528\u9632\u6cbb\u6742\u5fd7]"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0022|cit22","first-page":"178","article-title":"A comparative study of olanzapine combined with low-dose magnesium valproate sustained-release tablets in the treatment of acute phrase of schizophrenia","volume":"21","author":"Li","year":"2008","journal-title":"Journal of Psychiatry [\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"7","key":"10.1002\/14651858.CD004028.pub4-BIB0023|cit23","first-page":"788, 798","article-title":"The effect of aripiprazole combined with magnesium valproate in the treatment of impulse control disorder of schizophrenia","volume":"38","author":"Li","year":"2009","journal-title":"Chongqing Medical Journal [\u91cd\u5e86\u533b\u5b66\u6742\u5fd7]"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0024|cit24","first-page":"151","article-title":"A study of additive effect of sodium-valproate in the treatment of schizophrenia","volume":"14","author":"Liang","year":"2004","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004028.pub4-BIB0025|cit25","first-page":"43\ufe634","article-title":"The effect of adjuvant magnesium valproate on schizophrenia","volume":"5","author":"Ma","year":"2010","journal-title":"China Practical Medicine [\u4e2d\u56fd\u5b9e\u7528\u533b\u836f]"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0026|cit26","first-page":"11, 596-7","article-title":"The effect of sodium valproate in participants with schizophrenia","volume":"70","author":"Liu","year":"2003","journal-title":"Chinese Journal of Clinical Medicinal Professional Research"},{"issue":"6","key":"10.1002\/14651858.CD004028.pub4-BIB0027|cit27","first-page":"490","article-title":"Sodium valproate in treatment of aggression for psychiatric participants","volume":"36","author":"Liu","year":"2007","journal-title":"Chongqing Journal of Medicine [\u91cd\u5e86\u533b\u5b66\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0028|cit28","unstructured":"Lu W Jin W Wang H Ma Y Tong Z Comparing study of sodium valproate xr (Depakine) in the supplementary therapy of excitement state in participants with schizophrenia and schizoaffective disorder Proceedings of the Zhejiang Annual Psychiatry Conference, Yiwu, China 2005 75 7"},{"issue":"15","key":"10.1002\/14651858.CD004028.pub4-BIB0029|cit29","first-page":"1291","article-title":"Clinical evaluation of sodium valproate xr (Depakine) in adjunctive therapy for participants with excitomania associated with schizophrenia and schizoaffective disorder","volume":"15","author":"Lu","year":"2006","journal-title":"Chinese New Drugs Journal"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0030|cit30","first-page":"203","article-title":"Sodium valproate combined clozapine in the treatment of refractory schizophrenia 34 cases","volume":"29","author":"Pan","year":"2010","journal-title":"Herald of Medicine [\u533b\u5b66\u5bfc\u62a5]"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0031|cit31","first-page":"398","article-title":"A study of olanzapine combined with magnesium valproate sustained-release tablets for the treatment of excitement and agitation in acute phase of schizophrenia","volume":"22","author":"Shi","year":"2010","journal-title":"Modern Practical Medicine [\u73b0\u4ee3\u5b9e\u7528\u533b\u5b66]"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0032|cit32","first-page":"10","article-title":"Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics","volume":"11","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0033|cit33","first-page":"250","article-title":"The effect of adjuvant magnesium valproate sustained-release tablets in the treatment of schizophrenia","volume":"19","author":"Wang","year":"2009","journal-title":"Journal of Clinical Psychiatry [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"5","key":"10.1002\/14651858.CD004028.pub4-BIB0034|cit34","first-page":"548","article-title":"A comparative study of sodium valproate combined with other drugs for schizophrenia with impulsive and aggressive behavior","volume":"22","author":"Wang","year":"2010","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00004714-200006000-00011","article-title":"Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia","volume":"20","author":"Wassef","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0036|cit36","first-page":"191","article-title":"The effect of adjuvant magnesium valproate sustained-release tablet in the treatment of schizophrenic participants with aggressive behaviours","volume":"21","author":"Xie","year":"2011","journal-title":"Journal of Clinical Psychiatry [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"22","key":"10.1002\/14651858.CD004028.pub4-BIB0037|cit37","first-page":"2713","article-title":"Short-term efficacy of risperidone combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia with aggressive behavior","volume":"26","author":"Yao","year":"2010","journal-title":"Occupation and Health [\u804c\u4e1a\u4e0e\u5065\u5eb7]"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0038|cit38","first-page":"92","article-title":"A double-blind comparative study of sodium valproate in treating of TD","volume":"14","author":"Yin","year":"2004","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0039|cit39","first-page":"265","article-title":"The effect of debakin combined with risperidone in the treatment of schizophrenia with psychmotor excitement","volume":"22","author":"Zhang","year":"2007","journal-title":"Medical Journal of Qilu [\u9f50\u9c81\u533b\u5b66\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0924-977X(99)80119-9","article-title":"Efficacy and tolerability of gabapentin (GBP) and valproate (VPA) as an adjunct in the neuroleptic treatment of acute manic syndromes","volume":"9","author":"Alberti","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial","volume":"12","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disorders"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ajp.151.1.123","article-title":"Serum concentrations of clozapine and its major metabolites: effects of co-treatment with fluoxetine or valproate","volume":"151","author":"Centorrino","year":"1994","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0043|cit43","first-page":"501","article-title":"Changes in direct measures of adiposity in schizophrenia participants during divalproex augmentation of antipsychotic treatment","volume":"33","author":"Haupt","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD004028.pub4-BIB0044|cit44","first-page":"43","article-title":"The effect of adjuvant magnesium valproate in the treatment of schizophrenia","volume":"5","author":"Ma","year":"April 2010","journal-title":"China Practical Medicine [\u4e2d\u56fd\u5b9e\u7528\u533b\u836f]"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0045|cit45","first-page":"101","article-title":"Valproate-diazepam combination versus chlorpromazine: a double-blind study in schizophrenic and schizophreniform disorders","volume":"17","author":"Monfort","year":"1991","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0046|cit46","unstructured":"NCT00183443 Divalproex extended release and placebo, lithium, or quetiapine for mania clinicaltrials.gov\/ct2\/show\/NCT00183443"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0047|cit47","first-page":"208","article-title":"A controlled study of sodium valproate and chlorpromazine for schizophrenia","volume":"6","author":"Ping","year":"1994","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0163-8343(00)00055-4","article-title":"Second generation antipsychotics in the emergency care setting. A prospective naturalistic study","volume":"22","author":"Raja","year":"2000","journal-title":"General Hospital Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD004028.pub4-BIB0049|cit49","first-page":"100","article-title":"The impact of sodium valproate for social function rehabilitation in schizophrenia participants","volume":"5","author":"Rifang","year":"2001","journal-title":"Modern Rehabilitation"},{"issue":"12","key":"10.1002\/14651858.CD004028.pub4-BIB0050|cit50","first-page":"934","article-title":"Sodium valproate and clonazepam for the treatment of agitated symptoms of participants with schizophrenia: a controlled trial","volume":"16","author":"Zhu","year":"2005","journal-title":"Medical Journal of the Chinese People's Armed Police Forces"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Boylan L Labovitz D Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia Neuropyschopharmacology 2004 636","DOI":"10.1038\/sj.npp.1300368"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0052|cit52","unstructured":"Chien C Jung K Ross-Townsend A Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia Psychopharmacology Bulletin 1978 20 2"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0053|cit53","unstructured":"Cui LJ Shen WM Effects of magnesium valproate treatment on weight and blood insulin levels in patients with schizophrenia Frontiers of Medicine [\u533b\u836f\u524d\u6cbf] 2012 97"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0054|cit54","unstructured":"Ellenor G Lohr J Ito M Dishman B Gammariello A The comparative efficacy of divalproex low and high serum level in bipolar disorder and schizophrenia Psychopharmacology Bulletin 1995 563"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-0447.1983.tb00339.x","article-title":"Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo","volume":"67","author":"Friis","year":"1983","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0056|cit56","unstructured":"Gong Y Guo P Effects of magnesium valproate on cognitive function in patients with refractory schizophrenia Chronic Pathematology Journal [\u6162\u6027\u75c5\u5b66\u6742\u5fd7] 2010 107 9"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0057|cit57","unstructured":"Gu P Wang J Cao J Li B-z A comparative study of quetiapine with sustained-release tablets of magnesium valproate in treatment of old patients with acute phase of schizophrenia Chinese Journal of Clinical Psychology [\u4e2d\u56fd\u4e34\u5e8a\u5fc3\u7406\u5b66\u6742\u5fd7] 2012 520 2"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0058|cit58","unstructured":"Gu Q Prognostic analysis of magnesium valproate combined with antipsychotics for patients with convalescent schizophrenia Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66] 2014 59, 99"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0059|cit59","unstructured":"Huang WD Luo HF Lan L Li CH Xu LH Li ZM Efficacy of ziprasidone combined with low-dose sodium valproate in the treatment of female refractory schizophrenia Youjiang Medical Journal [\u53f3\u6c5f\u533b\u5b66] 2013 159 62"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0060|cit60","unstructured":"Jiang TC Xiong Y Efficacy of quetiapine combined with sodium valproate in the treatment of schizophrenia with impulsive and aggression in female patients World Latest Medicine Information [\u4e16\u754c\u6700\u65b0\u533b\u5b66\u4fe1\u606f\u6587\u6458\uff08\u8fde\u7eed\u578b\u7535\u5b50\u671f\u520a\uff09] 2014 79 80"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0061|cit61","unstructured":"Jin G Efficacy of magnesium valproate for schizophrenia with impulsive and aggressive behavior Chinese Journal of Modern Drug Application [\u4e2d\u56fd\u73b0\u4ee3\u836f\u7269\u5e94\u7528] 2013 160 1"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0062|cit62","unstructured":"Lee MS Choi BH Kim SH Combined use of carbamazepine and valproic acid in negative symptom schizophrenia 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands 1996 83227217"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0063|cit63","first-page":"178","article-title":"A comparative study of olanzapine with small-dose sustained-release tablets of magnesium valproate in treatment of acute phase of schizophrenia","volume":"21","author":"Li","year":"2008","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0064|cit64","unstructured":"Li DM Clinical efficacy of ziprasidone combined with valproate in the treatment of refractory schizophrenia China Medical Engineering [\u4e2d\u56fd\u533b\u5b66\u5de5\u7a0b] 2012 92 3"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0065|cit65","unstructured":"Li C Liu Y Wang M The effect of adjuvant magnesium valproate sustained-release tablets combined with risperidone in the treatment of schizophrenia with impulsive aggression Journal of Practical Medical Techniques [\u5b9e\u7528\u533b\u6280\u6742\u5fd7] 2013 69 71"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0066|cit66","unstructured":"Li J Chen LS Chen Wang Y A comparative study of effect of sodium valproate on cognitive dysfunction in patients with schizophrenia Journal of Psychiatry [\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2013 292 4"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0067|cit67","unstructured":"Li YM Sun WB Yang CQ A study of low-dose quetiapine combined with magnesium valproate in the treatment of schizophrenia Medical Information [\u533b\u5b66\u4fe1\u606f] 2014 47 8"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0068|cit68","unstructured":"Li Y A comparative study of antipsychotic drugs combined with low-dose sodium valproate in the treatment of schizophrenia The Chinese and Foreign Health Abstract [\u4e2d\u5916\u5065\u5eb7\u6587\u6458] 2014 53"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0069|cit69","first-page":"92","article-title":"A study of additive effect of sodium-valproate in the treatment of schizophrenia","volume":"14","author":"Liang","year":"2004","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1192\/bjp.129.2.114","article-title":"Effect of sodium valproate on tardive dyskinesia","volume":"129","author":"Linnoila","year":"1976","journal-title":"British Journal of Psychiatry"},{"issue":"Nov","key":"10.1002\/14651858.CD004028.pub4-BIB0071|cit71","first-page":"33","article-title":"Sodium valproate therapy for tardive dyskinesia","volume":"11","author":"Linnoila","year":"1976","journal-title":"International Drug Therapy Newsletter"},{"issue":"6","key":"10.1002\/14651858.CD004028.pub4-BIB0072|cit72","first-page":"490","article-title":"Sodium valproate in treatment of aggression of psychiatric participants","volume":"36","author":"Liu","year":"2007","journal-title":"Chongqing Medical Journal [\u91cd\u5e86\u533b\u5b66]"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0073|cit73","unstructured":"Liu Z Wang L Sun Y Clinical observation of magnesium valproate sustained-release tablets for schizophrenia with excitement China Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7] 2012 1630 1"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0074|cit74","unstructured":"Liu J The effect of adjuvant magnesium valproate on schizophrenia with aggressive behavior Journal of Community Medicine [\u793e\u533a\u533b\u5b66\u6742\u5fd7] 2012 31 2"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0075|cit75","unstructured":"Liu Z Song S Wang L Effects of magnesium valproate sustained-release tablets combined with risperdal on lipid metabolism in patients with schizophrenia China Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7] 2013 1631 2"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0076|cit76","unstructured":"Liu Z Li HJ Pei SY Effects of risperidone and magnesium valproate on blood concentration in patients with schizophrenia China Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7] 2014 1141 3"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0077|cit77","unstructured":"Lv S Effects of magnesium valproate sustained-release tablets on cognitive function in first-episode schizophrenic patients China & Foreign Medical Treatment [\u4e2d\u5916\u533b\u7597] 2014 120 1"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0078|cit78","unstructured":"Ma TB Analysis of effects of valproic acid sodium jointed with ziprasidone in the treatment of refractory schizophrenia China Modern Medicine [\u4e2d\u56fd\u5f53\u4ee3\u533b\u836f] 2012 73 4"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Monteleone P Maj M Iovino M Steardo L Growth hormone response to sodium valproate in chronic schizophrenia Biological Psychiatry 1986 588 94","DOI":"10.1016\/0006-3223(86)90119-8"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"Monteleone P Maj M Ariano M Iovino M Fiorenza L Steardo L Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia Psychopharmacology 1988 223 6","DOI":"10.1007\/BF00177564"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0081|cit81","first-page":"437","article-title":"Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies","volume-title":"Long Term Effects of Neuroleptics. Advances in Biochemistry and Psychopharmacology","volume":"24","author":"Nair","year":"1980"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0082|cit82","unstructured":"Nasrallah H Dunner F McCalley Whitters M Smith R Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management Journal of Clinical Psychological Medicine 1986 56 9"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0083|cit83","unstructured":"NCT00552500 Effects of atypical antipsychotic and valproate combination therapy on glucose and lipid metabolism in schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00552500"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0084|cit84","unstructured":"Peng ZY Xia CL Liu XM A comparative study of clozapine and clozapine unite magnesium valproate in the treatment of patients with treatment-resistant schizophrenia World Health Digest Medical Periodieal [\u4e2d\u5916\u5065\u5eb7\u6587\u6458] 2012 164 6"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0085|cit85","unstructured":"Peng H Effect of magnesium valproate on aggressive behavior in schizophrenia Chinese Journal of Trauma and Disability Medicine [\u4e2d\u56fd\u4f24\u6b8b\u533b\u5b66] 2013 187 8"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0086|cit86","unstructured":"Pu QX Wu HB Huang X Yu GH Wang DF Gu ZW Contrast analysis of olanzapine combined with sodium valproate on refractory schizophrenia Progress in Modern Biomedicine [\u73b0\u4ee3\u751f\u7269\u533b\u5b66\u8fdb\u5c55] 2013 3503 6"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0087|cit87","unstructured":"Qiu LL Wang JF Effect of sodium valproate on risperidone therapy and blood concentration Medical Journal of Liaoning [\u8fbd\u5b81\u533b\u5b66\u6742\u5fd7] 2014 9 10"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0088|cit88","unstructured":"Qu CH Liu XL Sun XH A comparative study of valproate combined with olanzapine in the treatment of schizophrenia Medical Information [\u533b\u5b66\u4fe1\u606f] 2014 602"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.psiq.2010.07.002","article-title":"Pharmacological augmentation strategies in clozapine-resistant schizophrenia: overcoming the resistance","volume":"17","author":"Ruiz-Doblado","year":"2010","journal-title":"Psiquiatria Biologica"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0090|cit90","unstructured":"Shu Z Zhou W Clinical observation of clozapine combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia Guide of China Medicine [\u4e2d\u56fd\u533b\u836f\u6307\u5357] 2014 28 9"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0091|cit91","unstructured":"Su L Xu Y Shi S Dutt A Bramon E Effects of chlorpromazine, clozapine and valproate on auditory P300 in schizophrenia: a prospective longitudinal randomized controlled study Schizophrenia Bulletin 2013 S51"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0092|cit92","unstructured":"Sun Q Quo H Zhang H Liu Y Zhu Y Zhang A The effects of magnesium valproate sustained release tablets on the cognitive function in treatment-resistant schizophrenic participants Proceedings of the Shanghai Regional Meeting and CSP Annual Congress; 2007 Sep 20-23; Shanghai 2007"},{"issue":"22","key":"10.1002\/14651858.CD004028.pub4-BIB0093|cit93","first-page":"25","article-title":"Effect of magnesium valproate sustained release tablets on cognition function in difficult cure sex schizophrenic","volume":"2","author":"Sun","year":"2008","journal-title":"Chinese Journal of Modern Drug Application [\u4e2d\u56fd\u73b0\u4ee3\u836f\u7269\u5e94\u7528]"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0094|cit94","unstructured":"Sun XG A comparative study of quetiapine combined with haloperidol, sodium valproate and clozapine in the treatment of refractory schizophrenia Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66] 2012 1566 7"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Suzana S Olivera Z Gordana N Violeta S Dragoslava G Vladica S Adjunctive mood stabilising treatment: the effects on hostility and impulsivity among patients with schizophrenia European Neuropsychopharmacology 2009 S532","DOI":"10.1016\/S0924-977X(09)70845-4"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0096|cit96","unstructured":"Tang SY Qin CL Zhang W Xiong MQ Clinical observation of sodium valproate sustained-release tablets on schizophrenia hostile attack J Medical Forum [\u533b\u836f\u8bba\u575b\u6742\u5fd7] 2012 36 7"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0097|cit97","first-page":"10","article-title":"Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics","volume":"11","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0098|cit98","first-page":"441","article-title":"Therapeutic effect of risperidone combined with magnesium valproate in aggressive behaviors of schizophrenics","volume":"14","author":"Wang","year":"2006","journal-title":"Chinese Journal of Health Psychology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0099|cit99","unstructured":"Wang G Xie R Pei G A comparative study of quetiapine combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia with aggressive behavior Journal of Psychiatry [\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2012 59 60"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0100|cit100","unstructured":"Wang Y Efficacy of olanzapine combined with magnesium valproate in the treatment of schizophrenia Chinese Journal of General Practice [\u4e2d\u534e\u5168\u79d1\u533b\u5b66] 2013 730+749"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0101|cit101","unstructured":"Wang ML Jiang TC Clinical observation of risperidone combined with sodium valproate in the treatment of schizophrenia with impulse and aggressive behavior Clinical Rational Drug Use [\u4e34\u5e8a\u5408\u7406\u7528\u836f\u6742\u5fd7] 2013 72 3"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0102|cit102","unstructured":"Wang GL Fu PX Li XY Lin JX Ji QS Li ZJ A comparative study of the efficacy of risperidone combined with valproate sodium on the aggressive behavior of the patients with schizophrenia Chinese Journal of Drug Abuse Prevention and Treatment [\u4e2d\u56fd\u836f\u7269\u6ee5\u7528\u9632\u6cbb\u6742\u5fd7] 2014 200 2"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0103|cit103","unstructured":"Wang ZB The effect of adjuvant sodium valproate for schizophrenia with behavioral disorders Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66] 2014 57 8"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0104|cit104","unstructured":"Wen J Li Y Wang G Clinical efficacy and safety of quetiapine combined with magnesium valproate in the treatment of schizophrenia with aggressive behavior Medical Journal of Chinese Civil Administration [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66] 2013 55 6"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0105|cit105","unstructured":"Wu J Lin T Efficacy of magnesium valproate combined with quetiapine in the treatment of refractory schizophrenia Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease [\u5b9e\u7528\u5fc3\u8111\u80ba\u8840\u7ba1\u75c5\u6742\u5fd7] 2013 140 1"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0106|cit106","unstructured":"Wu X Yang Q Zhang L Zhou S A comparative study of olanzapine combined with magnesium valproate sustained-release tablets in the treatment of patients with positive symptoms of schizophrenia Medical Journal of West China [\u897f\u90e8\u533b\u5b66] 2013 1842 4"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0107|cit107","unstructured":"Xiao H A retrospective study of risperidone combined with magnesium valproate in the treatment of schizophrenia Nei Mongol Journal of Traditional Chinese Medicine [\u5185\u8499\u53e4\u4e2d\u533b\u836f] 2013 30 1"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0108|cit108","unstructured":"Xu HL Wang Y The effect of adjuvant sodium valproate on auditory hallucinations in schizophrenia Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2002 157 8"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0109|cit109","unstructured":"Xu LH Huang WD Li CH Ban RY Luo HF Li ZM Ziprasidone combined with low-dose sodium valproate in the treatment and nursing of female refractory schizophrenia Journal of Aerospace Medicine [\u822a\u7a7a\u822a\u5929\u533b\u5b66\u6742\u5fd7] 2013 1133 5"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0110|cit110","unstructured":"Xu BF Lou YM Cai XH Effects of magnesium valproate sustained-release tablets combined with clozapine in the treatment of female refractory schizophrenia Chinese Journal of Trauma and Disability Medicine [\u4e2d\u56fd\u4f24\u6b8b\u533b\u5b66] 2014 148 9"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0111|cit111","first-page":"265","article-title":"Therapeutic efficacy of combination of risperidone with Depakine for schizophrenia","volume":"22","author":"Zhang","year":"2007","journal-title":"Medical Journal of Qilu"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0112|cit112","unstructured":"Zhang DW Dai J Xie WF Chen WT Sodium valproate combined with EEG as an adjuvant therapy for schizophrenia Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66] 2007 1049, 1051"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0113|cit113","unstructured":"Zhang X Wang XM Magnesium valproate combined with risperidone in the treatment of schizophrenia with negative symptoms Chinese Journal of Misdiagnostics [\u4e2d\u56fd\u8bef\u8bca\u5b66\u6742\u5fd7] 2008 4361 2"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0114|cit114","unstructured":"Zhang X Ye CP Liu WP Efficacy of sodium valproate combined with haloperidol in the treatment of early schizophrenia Chinese and Foreign Medical Research [\u4e2d\u5916\u533b\u5b66\u7814\u7a76] 2012 38 9"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0115|cit115","unstructured":"Zhou YH Zhong YF Zeng DZ Dai LJ Efficacy of magnesium valproate sustained-release tablets combined with ziprasidone in the treatment of schizophrenia with aggressive behavior The 10th National conference of Psychiatry of Chinese Medical Association 2012 1"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0116|cit116","unstructured":"Zhou LC Nong YX Chen QM Effect and safety comparison of risperidone single therapy or combined valproate on excited restless of schizophrenia Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2013 261 2"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0117|cit117","unstructured":"Zhou W Xie WJ Hu YZ Clinical observation of olanzapine combined sustained-release magnesium valproate tablet treating male schizophrenic patients with aggressive behavior Journal of Clinical Psychiatry [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2014 194 6"},{"issue":"12","key":"10.1002\/14651858.CD004028.pub4-BIB0118|cit118","first-page":"934","article-title":"A comparative study of sodium valproate combined with clonazepam for schizophrenic agitation","volume":"16","author":"Zhu","year":"2005","journal-title":"Medical Journal of the Chinese People's Armed Police Forces [\u6b66\u8b66\u533b\u5b66]"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0119|cit119","unstructured":"Zhu YT Zeng DF A comparative study of antipsychotic drugs combined with low-dose sodium valproate in the treatment of schizophrenia China Practical Medicine [\u4e2d\u56fd\u5b9e\u7528\u533b\u836f] 2014 140 1"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0120|cit120","unstructured":"NCT00167934 Metabolic effects of valproate and antipsychotic therapy clinicaltrials.gov\/ct2\/show\/NCT00167934"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0121|cit121","unstructured":"NCT00306475 Does the addition of divalproex sodium ER to an atypical antipsychotic drug (APD) improve cognition and psychopathology in outpatients with schizophrenia (sch) or schizoaffective disorder (sad)? clinicaltrials.gov\/ct2\/show\/NCT00306475"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0122|cit122","first-page":"S173","article-title":"Valproate augmentation of antipsychotic therapy","volume":"3 (Suppl 1)","author":"Norrie","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0123|cit123","unstructured":"Wang G 60 week, randomized, double-blind, placebo-controlled trial of valproate added to risperidone in 200 treatment-naive, first-episode participants with schizophrenia Stanley Foundation Research Programs 2003"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000291496","article-title":"Scale for the assessment of negative symptoms","volume":"155","author":"Andreasen","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2003-39045","article-title":"Long-term treatment of schizoaffective disorder: review and recommendations","volume":"36","author":"Baethge","year":"2003","journal-title":"Pharmacopsychiatry\u00a0"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0128|cit128","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001945","article-title":"Ziprasidone for schizophrenia and severe mental illness","author":"Bagnall","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD004028.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","article-title":"Chemical properties of antiepileptic drugs (AEDs)","volume":"64","author":"Bailer","year":"2012","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/13651509909068391","article-title":"Valproic acid for seizure prophylaxis during clozapine therapy: where's the evidence?","volume":"3","author":"Balen","year":"1999","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials: the CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200629020-00001","article-title":"Interactions between antiepileptic and antipsychotic drugs","volume":"29","author":"Besag","year":"2006","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD004028.pub4-BIB0134|cit134","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0165-0327(02)00046-0","article-title":"The clinical use of gabapentin in bipolar spectrum disorders","volume":"75","author":"Carta","year":"June 2003","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000234","article-title":"Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)","author":"Cheine","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/schbul\/17.2.217","article-title":"When symptoms persist: choosing among alternative somatic treatments for schizophrenia","volume":"17","author":"Christison","year":"1991","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD004028.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1176\/appi.ps.51.5.634","article-title":"Changes in use of valproate and other mood stabilizers for participants with schizophrenia from 1994 to 1998","volume":"51","author":"Citrome","year":"2000","journal-title":"Psychiatric Services"},{"issue":"6","key":"10.1002\/14651858.CD004028.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2850.2002.00524.x","article-title":"Philosophy, care and treatment on the psychiatric intensive care unit: themes, trends and future practice","volume":"9","author":"Crowhurst","year":"2002","journal-title":"Journal of Psychiatric and Mental Health Nursing"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.316.7126.221","article-title":"Meta-analysis: unresolved issues and future developments","volume":"16","author":"Davey Smith","year":"1998","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004714-200002001-00001","article-title":"Comprehensive review of the psychiatric uses of valproate","volume":"20","author":"Davis","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0143|cit143","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0144|cit144","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' participant care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004028.pub4-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006391.pub2","article-title":"Benzodiazepines for schizophrenia","author":"Dold","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059.pub2","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1176\/ajp.155.1.12","article-title":"Mood stabilizer combinations: a review of safety and efficacy","volume":"155","author":"Freeman","year":"1998","journal-title":"The American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD004028.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0153|cit153","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002306","article-title":"Risperidone versus other atypical antipsychotic medication for schizophrenia","author":"Gilbody","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0154|cit154","volume-title":"Drug Class Review on Antiepileptic Drugs in Bipolar Mood Disorder, Neuropathic Pain, and Fibromyalgia","author":"Goodman","year":"2006"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0156|cit156","article-title":"ECDEU assessment manual for psychopharmacology","volume-title":"Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0158|cit158","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0159|cit159","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0160|cit160","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0161|cit161","volume-title":"Inpatient Multidimensional Psychiatric Scale. Eine multidimensionale Skala zur systematischen Erfassung des psychopathologischen Befundes (Dt. Version). Manual","author":"Hiller","year":"1986"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0162|cit162","article-title":"Positive and negative syndrome scale (PANSS) manual","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0163|cit163","first-page":"1","article-title":"Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry","volume":"262","author":"Konstantinos","year":"2012","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD004028.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003834.pub2","article-title":"Lithium for schizophrenia","author":"Leucht","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0168|cit168","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001258.pub2","article-title":"Carbamazepine for schizophrenia","author":"Leucht","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/pst.124","article-title":"Choice of the primary analysis in longitudinal clinical trials","volume":"3","author":"Mallinckrodt","year":"2004","journal-title":"Pharmaceutical Statistics"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment? A review","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"258","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0173|cit173","article-title":"Clinical Global Impression","volume-title":"Manual for the ECDEU Assessment","author":"National Institute of Mental Health","year":"1970"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0174|cit174","article-title":"ECDEU Assessment Manual for Psychopharmacology","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1991"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"6","key":"10.1002\/14651858.CD004028.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/01.yco.0000186017.72973.8c","article-title":"Clinical trial design in schizophrenia: implications for clinical decisions","volume":"18","author":"Pajonk","year":"2005","journal-title":"Current Opinion in Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a reexamination","volume":"62","author":"Palmer","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/00048679609076070","article-title":"Drug strategies and treatment-resistant schizophrenia","volume":"20","author":"Pantelis","year":"1996","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0179|cit179","first-page":"165","article-title":"The empirical basis of the use of antiepileptics in the treatment of bipolar disorder","volume":"1","author":"Perugi","year":"2004","journal-title":"Clinical Neuropsychiatry"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0180|cit180","first-page":"431","article-title":"Clinical research for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0182|cit182","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavia"},{"issue":"5","key":"10.1002\/14651858.CD004028.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients With insufficient response to clozapine: a quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/0929867043456070","article-title":"A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation","volume":"11","author":"Stahl","year":"2004","journal-title":"Current Medicinal Chemistry"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0187|cit187","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention . Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD004028.pub4-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000076.pub2","article-title":"Electroconvulsive therapy for schizophrenia","author":"Tharyan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004028.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002826-200601000-00010","article-title":"Somatic augmentation strategies in clozapine resistance - what facts?","volume":"29","author":"Tranulis","year":"2006","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD004028.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130100711","article-title":"Drop-out rates in randomised antipsychotic drug trials","volume":"155","author":"Wahlbeck","year":"2001","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD004028.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD004028.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.v65n0206","article-title":"Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Leucht","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004028.pub4-BIB0195|cit195","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004028.pub3","article-title":"Valproate for schizophrenia","author":"Schwarz","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004028.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:04:01Z","timestamp":1694419441000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004028.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":195,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004028.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}